Great praise! Five new Novartis drugs were approved in Japan on the same day: Tabrecta, Entresto, Mayzent, Enerzair and Atectura.

, 2020 /PRNewswire/
--Novartishas announced that Japan's Ministry of Health, Labour (MHLW) has approved five drugs simultaneously:-Tabrecta(capinmatib, caprectib, Originally known as INC280: The drug is an oral MET inhibitor used to treat patients with advanced and/or recurrent non-small cell lung cancer (NSCNC) who carry met exon 14 jump (MET exon 14 skipping, METex14) mutation-Entresto(Chinese product name: Nosinto, sacubitril/valsartan): used to treat chronic heart failure-Mayzent(Chinese Product Name: Wanlion, Generic Name: Siponimod, Sinimod): For the treatment of progressive multiple sclerosis (SPMS)-Enerzair(QVM149; indacaterol acetate/glycopyrronium bromide/mometasone furoate, acetate-datero/glon bromium/memison; IND/GLY/MF) and Astua (F149, IND/MF, acetamitatro-tato/medo
"Five new products were approved at the same time, which is great for Japan and our industry," said Kazunari Tsunaba, president and representative director of Novartis
pharmaceutical sagencyals at We are pleased to see that our innovative products are supported by leading regulators All five drugs are truly novel and transformative treatments, marking an important milestone in our mission to reimagine medicine I would like to thank my Japanese and global colleagues for their efforts to achieve this unprecedented milestone "
Novartis has received seven new product approvals in Japan so far this year In addition to today's five approvals, Novartis also received approval in March for the spinal muscular dystrophy (SMA) one-time gene therapy Zolgensma and wet-AMD anti-VEGF drug Beovu These approvals and today's unprecedented milestones demonstrate the strength
of novartis's innovative drug pipeline and the company's commitment to ensuring that Japanese patients have timely access to these life-changing drugs "(BioValleyBioon.com) original origin: Novart receivis s approval for five new products from the Japanese Ministry of Health, Labour and Welfare, offering japanese patients a broad range of novel soption .